Oncotelic Therapeutics Balance Sheet Health
Financial Health criteria checks 0/6
Oncotelic Therapeutics has a total shareholder equity of $11.6M and total debt of $12.6M, which brings its debt-to-equity ratio to 108.3%. Its total assets and total liabilities are $30.0M and $18.4M respectively.
Key information
108.3%
Debt to equity ratio
US$12.57m
Debt
Interest coverage ratio | n/a |
Cash | US$170.41k |
Equity | US$11.61m |
Total liabilities | US$18.40m |
Total assets | US$30.01m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: OTLC's short term assets ($271.7K) do not cover its short term liabilities ($16.5M).
Long Term Liabilities: OTLC's short term assets ($271.7K) do not cover its long term liabilities ($1.9M).
Debt to Equity History and Analysis
Debt Level: OTLC's net debt to equity ratio (106.8%) is considered high.
Reducing Debt: OTLC's debt to equity ratio has increased from 0% to 108.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: OTLC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: OTLC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.4% each year